| All (N = 187) | ICH (N = 31) | No ICH (N = 156) | p |
---|---|---|---|---|
Age, median (IQR) | 74 (60–81) | 77 (52–84) | 73 (62–80) | 0.592 |
Male sex | 86 (45.9) | 12 (38.7) | 19 (61.3) | 0.433 |
Hypertension | 119 (63.6) | 20 (64.5) | 99 (63.5) | 1.000 |
Diabetes mellitus | 24 (12.9) | 3 (9.7) | 21 (13.5) | 0.771 |
Atrial fibrillation | 112 (59.9) | 15 (48.4) | 16 (51.6) | 0.165 |
Cancer | 8 (4.4) | 1 (3.2) | 7 (4.6) | 1.000 |
Chronic kidney failure | 11 (6.1) | 1 (9.1) | 10 (6.6) | 0.694 |
Chronic heart failure | 25 (13.9) | 6 (24) | 20 (12.8) | 0.371 |
Admission values | ||||
 Pre-morbid mRS > 1 | 7 (3.7) | 3 (9.7) | 4 (2.6) | 0.091 |
 Body mass index (N = 156) | 25.4 (23.1–29.0) | 24.2 (21.9–27.8) | 25.7 (23.4–29.0) | 0.058 |
 NIHSS | 18 (13–22) | 18 (14–23) | 18 (13–22) | 0.311 |
 Occlusion site |  |  |  | 0.064 |
  M1 | 145 (77.5) | 20 (64.5) | 125 (80.1) |  |
  ACI + M1/M2 | 22 (22.5) | 11 (35.5) | 31 (19.9) |  |
 ASPECTS | 8 (8–9) | 8 (7–9) | 9 (8–9) | 0.226 |
 Serum glucose | 118 (107–142) | 123 (112–150) | 118 (106–142) | 0.290 |
 Neutrophil to lymphocyte ratio | 3.6 (2.1–5.8) | 5.1 (2.9.-8.4) | 3.2 (1.9–5.2) | 0.003 |
 Hyperdense thrombus area (N = 105) | 25.7 (15.3–45.2) | 34.0 (25.1–52.7) | 22.3 (13.6–41.8) | 0.039 |
Stroke etiology | Â | Â | Â | 0.075 |
 Cardioembolic and unknown | 153 (81.8) | 29 (93.5) | 124 (75.4) |  |
 Large artery atherosclerotic + other etiology | 34 (18.2) | 2 (6.4) | 32 (20.5) |  |
Procedure related | ||||
 Intravenous thrombolysis | 133 (71.5) | 21 (67.7) | 112 (72.3) | 0.664 |
 Time to first imaging, min | 95 (65–132) | 107 (83–155) | 88.5 (64–128) | 0.045 |
 Time to needle | 112 (85–150) | 135 (110–167) | 105 (82–140) | 0.034 |
 Time to groin puncture | 189 (148–233) | 205 (180–252) | 186 (144–227) | 0.073 |
 Number of passes > 3 | 76 (50.0) | 16 (59.3) | 60 (48.0) | 0.396 |
 Intervention time | 52 (25–93) | 70 (35–116) | 50 (21–85) | 0.059 |
 ICA Stenting | 15 (28.3) | 2 (22.2) | 13 (29.5) | 1.000 |
 TICI 2b or 3 | 141 (75.8) | 20 (64.5) | 11 (35.5) | 0.114 |